Background: Most of the studies of the treatment of nonmetastatic osteosarcoma of the extremity have reported results in terms of probability of survival up to five years with a minimum follow-up of less than two to three years. Definition of reliable indicators of prognosis and predictive factors for survival require mature data derived from a long-term survival analysis.
Introduction
Randomized and non-randomized studies [1] [2] [3] [4] [5] [6] have demonstrated the primary role of chemotherapy in the treatment of non-metastatic osteosarcoma of the extremity. However, most of these studies reported their results in terms of probability of survival up to five years calculated on study populations whose minimum follow-up was less than two to three years, and only for the Multi-Institutional Osteosarcoma Study (MIOS) have the results been updated [7] .
Analysis of these data yielded useful information on the efficacy of different chemotherapy treatments, but determination of dependable indicators of prognosis and predictive factors for survival require mature data derived from a long-term survival analysis.
Our objective was to update the results obtained in a study population of 127 patients with non-metastatic osteosarcoma of the extremity, treated with neoadjuvant chemotherapy between March 1983 and June 1986 and to evaluate the predictive factors for survival.
The early results of this study (IOR/OS/I), updated to December 1988, were published in 1990 [8] .
Patients and methods
The criteria of eligibility for the study were the following: biopsyproven classic high-grade osteosarcoma of the extremity, age younger than 50, absence of metastasis, no prior history of cancer and no prior chemotherapy or surgical treatment for the bone lesion.
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For randomization, patients were stratified according to the proximal (upper third of femur or humerus) or distal location of the tumor.
The second aim of the study was to evaluate postoperative chemotherapy treatments in relation to the histologic response to primary chemotherapy. /daily for two days; GR -good responder patients (tumor necrosis ^ 90%); FR -fair responder patients (tumor necrosis ranging between 60-89%); PR -poor responder patients (tumor necrosis < 60%). Since February 1984 good responder patients had the same treatment of fair responder patients.
The pre-treatment patient evaluation comprised medical history and physical examination, complete blood cell count, liver function tests, and determination of serum creatinine, electrolytes, serum alkaline phosphatase (SAP), and lactic dehydrogenase (LDH).
The primary tumor was evaluated with plain roentgenograms and computed tomography (CT) scans; angiograms were performed if indicated by the choice of surgical procedure.
Computed tomography or whole lung tomography and bone scintigraphy were used to exclude metastases.
The type of surgery (amputation or limb salvage) as well as the type of reconstruction for patients treated for limb salvage (prosthesis, allogTaft, vascularized graft) were chosen according to location and extent of the tumor, and the patient's age and desired life style.
In any case, for conservative surgery, it was mandatory that the preoperative staging assure achievement of adequate surgical margins.
Surgical margins of the resected specimen and histologic response to primary chemotherapy were assessed at the study Institution.
Surgical margins were classified as radical, wide, marginal and intralesional according to Enneking et al.'s criteria [9] .
The histologic response to primary chemotherapy was rated 'good' (equal to or more than 90% tumor necrosis), 'fair' (60%-89% tumor necrosis) or 'poor' (less than 60% tumor necrosis) and evaluated according to a method previously reported [10] .
After chemotherapy completion, patients were followed every two months for two years, every three months during the third year, every four months during the fourth year, and then every six months, with radiographs of the stump or the resected limb, and radiographs of the chest.
The diagnostic and surgical procedures and the follow-up were centralized at the study Institution.
The chemotherapy treatment was administered in the Chemotherapy Division of the Rizzoli Institute. Two Oncologic Centres (the Paediatric Divisions of the Universities of Bologna and Torino) cooperated for chemotherapy treatments.
IOR/OS/I was a randomized study projected to compare the efficacy of high-dose methotrexate (HDMTX) versus moderate-dose methotrexate (MDMTX) in a chemotherapy regimen consisting of cisplatin (CDP), doxorubicin (ADM), bleomycin, cyclophosphamide and dactinomycin (BCD).
Chemotherapy
The chemotherapy regimen of IOR/OS/I is outlined in Figure 1 . Preoperatively, patients received two courses of MTX and CDP.
MTX was given intravenously (i.v.) on day 1; patients were randomized to receive HDMTX (7.5 g/m 2 in a six-hour infusion) or MDMTX (750 mg/m 2 in a 30-minute infusion). In both cases, citrovorum factor rescue was started 24 hours after the beginning of MTX infusion. In patients who were given HDMTX, hydration was performed during the first 24 hours after administration of the drug according to Rosen et al.'s guidelines [11] .
On day 7 CDP (120 mg/m 2 ) was intraarterially (i.a.) delivered in a 72-hour continuous infusion.
A second course of MTX and CDP was repeated after a 14-day interval
The start of post-operative chemotherapy was scheduled for one week after amputation or three weeks after a limb-salvage procedure.
According to the histologic response to primary chemotherapy, patients received different treatments.
Patients with a good histologic response (GR) were given two cycles of MTX and CDP IV, with the same doses and schedule as in the preoperative phase.
Patients with a fair histologic response (FR) were given three cycles of MTX and CDP i. 
Statistical analysis
The disease-free survival (DFS) was calculated from the first day of chemotherapy until recurrence (local or distant) or until the last followup examination. Overall survival (OS) was calculated from the first day of chemotherapy until death of the disease or the last follow-up.
The survival curves were calculated according to the KaplanMeier method and compared by means of the log-rank test.
The Cox proportional hazards regression analysis was used for multivariate analysis to test predictive factors for survival.
The frequency of the distribution of different parameters was compared among groups of patients by means of the chi-square test. Significance was set at P < 0.05.
Results
Between March 1983 and June 1986, 242 patients with osteosarcoma were registered at the study Institution, and 170 of them were eligible for the study.
Thirty-two of the eligible patients declined to enter the study and were treated with immediate surgery followed by adjuvant chemotherapy.
Eleven of the 138 patients who entered the study were not evaluable.
Five patients refused surgery and moved to another hospital for local treatment with hyperthermic antiblas- tic perfusion with CDP (300 mg/m 2 ); all of them died of uncontrolled disease. Five patients refused chemotherapy after the first cycle of MTX (three cases) or after surgery (two cases). Three of these patients underwent limb-salvage procedures and two amputatations. Lung metastases developed in these patients 10 to 24 months after sugery. One patient died of a pulmonary embolism immediately after a limb-salvage procedure.
The remaining 127 eligible patients were evaluable for the survival analysis.
Sixty-seven patients were randomized to receive HDMTX and 60 to receive MDMTX.
The clinical features of the evaluable patients are reported in Table 1 .
Surgery and histologic response to primary chemotherapy
One-hundred twenty-six patients underwent surgery.
Progression of disease and lung metastasis developed in one patient in the HDMTX group during the preoperative phase of treatment. This patient was moved to another hospital for lung metastasectomy and local treatment with hyperthermic perfusion with CDP: he died six months later of uncontrolled disease.
Ninety-one patients (72%) underwent limb-salvage surgical procedures, three (2%) had a rotation-plasty and 32 patients (26%) had amputations.
Adequate surgical margins (radical or wide) were achieved in 113 patients (90%): in 101 the margins were wide and in 12 were radical. In 13 patients (10%) surgical margins proved to be inadequate (marginal nine patients, intralesional four patients).
Of the 126 patients who underwent surgery, 66 (52%) had good histologic responses (> 90% tumor necrosis) to primary chemotherapy; 45 (36%) had a tumor necrosis ranging from 60% to 89% (fair responders) and 15 patients (12%) had poor histologic responses (tumor necrosis <60%).
According to the dose of MTX, good histologic re- sponse was observed in 41 (62%) of the 66 patients who received HDMTX and in 25 (42%) of the 60 patients treated with MDMTX (P < 0.04).
Disease-free survival
With a median follow-up of 134 months (range 114-153), 58 of the 127 evaluable patients (46%) were continuously free of disease, and 69 patients (54%) had distant or local recurrences. The median time to recurrence was 14 months (range 2-96).
Sixty-three patients (50%) relapsed with metastases only: in 58 cases (92%) the first site of metastases were the lungs, in 4 (6%) the skeleton, one patient developed (2%) epidural metastases.
Local recurrence developed in six of the 126 operated patients (5%) and in four cases it was associated with lung metastases.
The median time to local recurrence was 10 months (range .
Local recurrences were observed in 2 (1.7%) of 113 patients with adequale surgical margins and in 4 (30.7%) of 13 patients with inadequate surgical margins (P < 0.001).
According to the tumor necrosis, the incidence of local recurrence was 1.5% (1 of 66) in GR patients, 6.6% (3 of 45) in FR patients and 13.3% (2 of 15) in PR patients (P = 0.147).
The 12-year probability of DFS was 46% (Figure 2 ). At univariate analysis no significant differences in terms of DFS were found according to age (comparisons were performed according to different age groups: ^15 vs. <15, 5*21 vs. <21, = 30 vs. <30), site {femur vs. humerus vs. tibia vs. other), size (=150 ml vs. < 150 ml) or histologic subtype (osteoblastic vs. chondroblastic vs. telangiectatic vs. others) of the tumor.
The histologic response to primary chemotherapy (Figure 3 ) influenced the DFS, with a 12-year DFS of 61% for GR patients, 35% for FR patients and 13% for PR patients (P = 0.0004).
According to the baseline serum value of alkaline Abbreviations: GR -good responder patients (tumor necrosiŝ 90%); FR -fair responder patients (tumor necrosis ranging between 60-89%); PR -poor responder patients (tumor necrosis < 60%); log-rank P = 0.0004. GR vs. FR: log-rank P = 0.0022. GR vs. PR: log-rank P = 0.0003. FR vs. PR: log-rank P -0.2823. phosphatase, patients with normal value by age had a 12-year DFS higher than the one obtained in patiens with high SAP level (56% vs. 39%; P = 0.0577). According to the serum LDH level (Figure 4 ), patients with LDH lower than 460 U/l had better DFS than patients with higher levels (55% vs. 29%; P -0.0013). The DFS curves according to MTX dose ( Figure 5 ) showed an advantage for patients who received HDMTX in comparison with those treated with MDMTX (52% vs. 38%; P = 0.0633).
A multivariate analysis including the factors that, in addition to univariate analysis, appeared to be predictive of DFS (tumor necrosis, SAP, LDH, and MTX dose), was performed ( Table 2) .
The chemotherapy-induced tumor necrosis (< 90% vs. 90% tumor necrosis) was the most important predictive factor for DFS (P = 0.0001) followed by baseline LDH serum level (Js460 U/l vs. <460 U/l; P = 0.0003). The MTX dose revealed a statistical significance (P -0.0441) whereas SAP lost the predictive significance for DFS it had appeared to have at the univariate analysis.
Overall survival and post-relapse survival
With a median time of observation for survivors of 130 months, the 12-year overall survival was 53% (Figure 2) for the 127 evaluable patients (48% (67 of 138) including patients who entered the study but were considered nonevaluable because of major protocol violations).
None of patients who relapsed with local recurrence or with secondary disease other than lung metastases is now alive.
The actuarial post-relapse survival was 19% at two years and 13% at 10 years after the first recurrence.
The time to relapse significantly influenced the postrelapse survival.
Patients with a relapse-free interval longer than 24 months had a 40% eight-year survival, whereas those with a shorter relapse-free interval had a 7% eight-year survival^ = 0.0159).
While the post-relapse outcome of all patients has been recorded, in only 50 cases (72.5%) has the treatment after relapse been recorded.
Twenty-four patients (48%) whose metastases were considered resectable underwent surgical treatment; in four patients it was combined with chemotherapy, and in one with radiation therapy. Due to the site or the extent of the secondary disease, surgical treatment was not considered feasible in the remaining 26 patients (52%), all of whom were treated with chemotherapy and/or radiation therapy.
The chemotherapy planned for relapsing patients was based on the first-line treatment: those patients who had previously received M-DMTX were given HDMTX, GR and FR patients received BCD and the GR patients who were not given ADM were treated with this drug.
The surgical treatment influenced the post-relapse survival.
All patients who were not surgically treated had disease progression and died within 40 months after the first recurrence.
Thirty percent of the surgically-treated patients had a 10-year probability of post-relapse survival.
Nine (37%) of 24 patients who underwent metastasectomy were alive, six of them free of disease after the first surgical procedure, two after a second thoracothomy and one with uncontrolled disease after the third thoracothomy.
Discussion
The results achieved with the IOR/OS/I protocol are similar to those obtained with similar protocols based on MTX, BCD, CDP, ADM and derived from the T-10 protocol [11] .
In the CCG-782 study [12] , patients were preoperatively treated with HDMTX, vincristine (VCR) and BCD; the postoperative treatment consisted of a common phase based on MTX, BCD and ADM, and a subsequent phase differentiated according to histologic response: patients with more than 95% tumor necrosis (good histologic response) were given MTX, BCD and ADM while the others received a 'salvage chemotherapy' with CDP, ADM and BCD. Twenty-eight percent of the patients had good histologic response. An eight-year event-free survival of 53% and an eight-year OS of 60%, were obtained. Patients with good histologic response had significantly better prognoses than patients with a poor histologic response.
Saeter et al. [13] reported similar results with a similar protocol: 17% of patients had good histologic response to a primary chemotherapy based solely on HDMTX; the five-year relapse-free survival was 54% and the OS was 64%. The histologic response to primary chemotherapy proved to be an important prognostic factor also in this study.
In the cooperative osteosarcoma study (COSS)-82 study [14] , 26% of patients preoperatively treated with HDMTX and BCD showed good histologic response; the four-year metastasis-free survival (MFS) was 49%; good-responder patients, postoperatively treated with the same drugs preoperatively employed, had a four-year MFS of 73%, whereas poor-responder patients who received a 'salvage chemotherapy' with CDP and ADM had a four-year MFS of 41%.
In our study, patients were preoperatively treated with MTX and i.a. CDP. The percentage of patients with good histologic response (^ 90% tumor necrosis) was 52% (62% in those patients who were randomized to receive HDMTX). This high percentage of good histologic response, superior to that reported in the previous studies, was obtained "because of the preoperative use of CDP and its intraarterial administration.
Despite this high percentage of good responders to primary chemotherapy, the 12-year DFS and OS were 46% and 53%, respectively; for the patients who were treated with HDMTX, the 12-year DFS was 52% and the 12-year OS was 61%.
IOR/OS/I was in fact a randomized study to evaluate the role of high-dose MTX in the treatment of nonmetastatic osteosarcoma of the extremity.
After a multivariate analysis, a significant advantage for patients treated with HDMTX (7.5 g/m 2 ) was demonstrated in comparison with patients treated with MDMTX (750 mg/m 2 ) ( Table 2) . These results, achieved in a multidrug regimen, confirm the importance of HDMTX in the treatment of osteosarcoma.
A relationship between serum MTX concentration and tumor necrosis was reported by Saeter et al. [13] ; we observed a close relationship between values of MTX serum peak and tumor necrosis in subsequent studies [15] on patients treated with HDMTX (8-12 g/m 2 ). Moreover, a relationship between MTX serum peak and prognosis was found by us [16] and other authors [17, 18] .
A significant influence of dose intensity of HDMTX on the outcome of patients with osteosarcoma was found in the recently reported meta-analysis performed by Delepine [19] .
The role of HDMTX was discussed after the publication of the results of the first EOI study [20] in which two different chemotherapy regimens were compared: one was based on six cycles of CDP/ADM while the other comprised four cycles of CDP/ADM plus four cycles of HDMTX.
In terms of DFS, the first protocol was more effective than the second (five-year DFS: 57% vs. 41%, P -0.02).
These results led to a new study [21] comparing a chemotherapy protocol based only on CDP and ADM to a T-10 type chemotherapy regimen, with HDMTX, VCR, BCD, CDP and ADM. No differences were found between the two protocols in terms of progression-free survival (39% vs. 40%), or of OS (55% for both protocols).
The oncologic results of this study were inferior to those achieved in the previously-mentioned studies [12] [13] [14] and similar to those achieved in the moderate-dose MTX arm of our study (12-year DFS: 38%).
Even though they highlight the importance of CDP and ADM, with doses and schedules according to those in the EOI study, in our opinion they do not support a proposal of chemotherapy treatment of osteosarcoma based on CDP and ADM only and excluding HDMTX, because of the demonstrated activity of HDMTX on osteosarcoma.
Besides the use of HDMTX, in our study we found two additional significant factors which are predictive of DFS: the primary chemotherapy-induced tumor necrosis and the serum level of LDH.
With respect to rumor necrosis and DFS: patients with good histologic response to primary chemotherapy had 61% DFS, those with a tumor necrosis ranging between 60% and 89% (fair response) had a 35% DFS, whereas a 13% DFS was obtained in poor-responder patients (P = 0.0004).
These results confirmed the predictive significance of tumor necrosis in osteosarcoma, as has been reported in several studies [12] [13] [14] [20] [21] [22] and they clearly indicate the need of a differentiated and effective 'salvage chemotherapy' for poor-responder patients.
The use of ifosfamide in the postoperative treatment of poor-responder patients can be considered.
In fact, in our second study of neoadjuvant chemotherapy for non-metastatic osteosarcoma of the extremity [23] , the post-operative use of ifosfamide in patients who respond poorly to a primary chemotherapy based on HDMTX, CDP and ADM allowed them the same probabilty of DFS as that of good-responder patients (five-year CDFS: GR 71%, PR 57%); similar results have been reported by Benjamin et al. [24] .
The baseline serum level of LDH showed an independent prognostic significance for DFS (P = 0.0013): patients with normal LDH levels had 55% DFS, whereas those with higher levels had 29% DFS.
Similar results have been reported by Meyers et al. [22] and Link et al. [7] .
SAP level was a significant predictive factor for DFS at the univariate analysis only, but it lost predictive significance after multivariate analysis (Table 2) . These data are in contrast to those reported in the MSKCC experience [22] .
Other factors such as sex, tumor site and tumor size, which were considered significant predictive factors for survival by several authors [25] [26] [27] showed no significant importance in our study.
The long-term follow-up of our study population showed a sort of biphasic pattern of relapse.
The curve of DFS was characterized by a first phase corresponding to the first two years after the start of treatment, with a rapid decrease of probability of DFS (two-year DFS 54%) followed by a second phase in which the DFS curve slowly decreased to a plateau reached by the eight-year (four-year DFS 48%, six-year DFS 47%, eight-and 12-year DFS 46%).
A similar pattern of relapse was described by the Scandinavian Sarcoma Group [28] and Cooperative Osteosarcoma Study [29] : with a median follow-up of 7.75 years, the plateau of DFS was reached at the eigth year of observation, whereas in the Memorial SloanKettering experience [22] the latest recurrence occurred in the ninth year of observation with the same follow-up of the previous studies.
Thus, there are possibilities of late relapse in nonmetastatic osteosarcoma; patients must be informed of this, and a long-term follow-up recommended.
Moreover, the possibility of late relapse has to be considered in evaluating the early results of new chemotherapy regimens.
The post-relapse survival was very poor, with twoand 10-year survivals of 19% and 13%, respectively.
A 25% two-year post-relapse survival was reported for the patients of the chemotherapy arm of the MultiInstitutional Osteosarcoma Study [7] .
Saeter et al. [28] reported a projected five-year survival rate of 24% from the first metastatic event in a population of 60 recurrent osteosarcoma; patients with local recurrence were excluded from this analysis.
Three factors appeared to influence post-relapse survival: the site of first recurrence, the possibility of appropriate surgical treatment and the relapse-free interval.
None of patients who relapsed with local recurrence or with metastases other than lung, survived.
The same results were reported by Ward et al. [30] .
In our study, a 30% 10-year survival was obtained in patients who could undergo appropriate surgical removal of lung metastases.
These results are similar to those reported in other studies: Beron et al. [31] reported a five-year survival rate of 36% for 22 patients who underwent complete metastasectomy. Huth et al. [32] reported a 23% four-year survival in patients who underwent metastasectomy, whereas none of the patients who were unable to undergo surgery survived. Ward et al. [30] reported a 23% fiveyear survival in patients who relapsed with lung metastasis only.
In our study, a relapse-free interval longer than 24 months was an important prognostic factor for postrelapse survival (RFI ^ 24 months: eight-year survival 40%, RFI <24 months: eight-year survival 7%, P = 0.0159).
In the SSG experience [28] a relapse-free interval longer than 21 months proved significant for survival. Ward et al. [30] found a better survival rate in patients with a relapse-free intervals longer than eight months.
The role of chemotherapy in relapsing patients with osteosarcoma has not been defined.
In our study, a further chemotherapy treatment (ADM, HDMTX and BCD) was administered in earlyrelapsing patients without improvement of their prognosis; however it must be stressed that most of these patients could not be treated with surgery.
Saeter et al. [28] found that an 'adequate' chemotherapy was a significant prognostic factor for survival, whereas other authors [7, 30, 32] were not able to demonstrate an influence of chemotherapy on post-relapse survival.
A promising activity of high-dose ifosfamide in recurrent osteosarcoma has recently been reported [33, 34] ; immunotherapy [35] or endocrine therapy [36] could be novel and interesting modalities of treatment for patients with metastatic osteosarcoma, nonetheless an adequate surgical removal of metastases is a necessary condition for survival.
